Study design and patients
advanced/metastatic NSCLC
This phase I, open-label study (NCT02668393) used a 3+3 dose-escalation design to explore the tolerability of second-line nintedanib plus weekly docetaxel in a 28-day cycle in patients with advanced/metastatic NSCLC. This study was conducted in four centers in France and Germany. Participant flow is shown in 